Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.
Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.